Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Rachel Humphrey"'
Autor:
Robert S. Williams, Rachel Humphrey
Publikováno v:
Online Learning, Vol 11, Iss 2 (2019)
This study (N=2,826 postings from 92 participants) examines the phenomenon of interactivity in asynchronous computer-mediated communication (ACMC), also known as threaded discussion, in the context of master’s level Teaching English as a Second Lan
Externí odkaz:
https://doaj.org/article/29f80b5a114b4f2381b8a4b61ed58e24
Autor:
F. Stephen Hodi, Rachel Humphrey, Geoffrey Nichol, Oliver Bohnsack, Michael Binder, Michele Maio, Celeste Lebbé, Omid Hamid, Jeffrey S. Weber, Steven O'Day, Axel Hoos, Jedd D. Wolchok
Purpose: Immunotherapeutic agents produce antitumor effects by inducing cancer-specific immune responses or by modifying native immune processes. Resulting clinical response patterns extend beyond those of cytotoxic agents and can manifest after an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4478970fcd76651243c3b3a282a13b
https://doi.org/10.1158/1078-0432.c.6517623.v1
https://doi.org/10.1158/1078-0432.c.6517623.v1
Purpose: This retrospective analysis was conducted to characterize ipilimumab exposure–response relationships for measures of efficacy and safety in patients with advanced melanoma.Experimental Design: Data were pooled from 498 patients who receive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8310bf802b39daba9071c1f1bcb13936
https://doi.org/10.1158/1078-0432.c.6521378.v1
https://doi.org/10.1158/1078-0432.c.6521378.v1
Basement membranes (BM) play fundamental roles in morphogenesis and tissue maintenance in multicellular organisms. Glutactin is a BM protein that belongs to the Cholinesterase-Like Adhesion Molecules (CLAMs) protein family. InDrosophilaembryos, Gluta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe6f60cd461ad8b67d2919abdab4b7b6
https://doi.org/10.1101/2022.11.30.518525
https://doi.org/10.1101/2022.11.30.518525
Autor:
Matthew C. Lucas, Melinda S. Merchant, Matthew O'Connor, Carl Cook, Sherri Smith, Anthony Trombino, Wu-Yan Zhang, Irache Visiers, Kate Tith, Reza Foroughi, Nigel Waters, Iwona Wrona, Michael Pickard, Sudharshan Eathiraj, Karsten Witt, Christopher Roberts, Rachel Humphrey, Elizabeth Buck
Publikováno v:
Molecular Cancer Therapeutics. 20:P02-04
NSCLC accounts for approximately 85% of lung cancer cases worldwide. NSCLC harboring EGFR mutations constitutes 10-20% of all lung cancer cases in Europe and North America, and up to 50% of those in Asia. The majority (80-90%) of these mutations are
Autor:
Rachel Humphrey, Alison M. Schram, Danny Nguyen, David S. Hong, Karsten Witt, Erika Hamilton, Leticia Tarilonte, Nigel J. Waters, Jasgit C. Sachdev, Shekeab Jauhari, Pasi A. Jänne, Manish R. Patel, Viola W. Zhu, Patricia LoRusso, Jordi Rodon Ahnert
Publikováno v:
Journal of Clinical Oncology. 39:3097-3097
3097 Background: Allosteric oncogenic mutations occur outside the canonical ATP-binding site of EGFR and HER2, and there are no approved therapies that target such mutations. BDTX-189 is a potent, selective, irreversible inhibitor of 48 allosteric EG
Autor:
Rachel Humphrey, Erika Hamilton, Patricia LoRusso, Shekeab Jauhari, Jasgit C. Sachdev, Nigel J. Waters, Pasi A. Jänne, Alison M. Schram, Jordi Rodon Ahnert, Danny Nguyen, Carl Cook, Xiuning Le, Matthew O'Connor, Viola W. Zhu, Manish R. Patel, Karsten Witt
Publikováno v:
Journal of Clinical Oncology. 39:3086-3086
3086 Background: BDTX-189 is an orally available, ATP-competitive and irreversible inhibitor directed against families of allosteric HER2 and EGFR oncogenic mutations. In preclinical studies BDTX-189 achieved potent inhibition of 48 allosteric HER2 a
Autor:
Emel Girit, Rachel Humphrey, Francis Y. Lee, Gregg Masters, Gennaro Dito, Maria Jure-Kunkel, John T. Hunt
Publikováno v:
Cancer Immunology, Immunotherapy
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) binding agent, has proven to be an effective monotherapy for metastatic melanoma and has shown antitumor activity in trials when administered with other therapeutic agents. We hypothesized that
Autor:
Mark Stroh, Karen A. Autio, Matthias Will, Rachel Humphrey, Beiyao Zheng, Valentina Boni, James Strauss, Johanna C. Bendell, Luc R. Desnoyers, Amy Weise, Naiyer A. Rizvi, Bert H. O'Neil, Alexander I. Spira, Nataliya Volodymyrivna Uboha, Lori Carman, Anthony B. El-Khoueiry, Aung Naing, Hendrik-Tobias Arkenau
Publikováno v:
Journal of Clinical Oncology. 36:3071-3071
3071Background: In single-agent trials, antibodies (Abs) targeting programmed cell death ligand 1 (PD-L1) improve survival in many cancers but are associated with immune-related toxicities (most co...
Autor:
Mark Stroh, Vanessa Huels, Rachel Humphrey, Matthias Will, Beiyao Zheng, Joshua F. Apgar, Bjorn L. Millard, Nancy Zheng, Hong Lu, Jennifer Richardson, Serwer Laura Patterson, Chihunt Wong
Publikováno v:
Journal of Clinical Oncology. 36:e14558-e14558
e14558Background: CX-072 is a protease-activatable antibody prodrug directed against programmed cell death ligand 1 (PD-L1). Probody therapeutics (Pb-Txs) are designed to be preferentially activate...